key: cord-0833710-4ot7gif8
authors: Alvarez-Mon, M.; Asunsolo, A.; Sanz, J.; Munoz, B.; Arranz-Caso, J. A.; Novella Mena, M.; Hernandez-Gutierrez, C.; Navarro, J.; Lozano Duran, M. C.; Arevalo Serrano, J.; Heche Sanchez, R.; Bravo Quiroga, L.; Flores Segovia, J.; Garcia Sanchez, M.; Gutierrez Garcia, A.; Perez, A.; Herrero, M.; Plana, N.; Troncoso, D.; Rackov, G.; Martinez-A, C.; Balomenos, D.
title: Tocilizumab efficacy in COVID-19 patients is associated with respiratory severity-based stages
date: 2021-03-09
journal: nan
DOI: 10.1101/2021.03.04.21252167
sha: 7554d3ddd2e6e1e5f24587f9eed00dd6c42346b5
doc_id: 833710
cord_uid: 4ot7gif8

Background: Tocilizumab treatment is investigated, and effectiveness in ICU-admitted COVID-19 patients has been reported. Although controversy exists regarding the efficacy of tocilizumab treatment, it has been suggested that tocilizumab might show positive results depending on patient severity status. We examined an association between tocilizumab and distinct disease severity stages. Methods and Findings: From March 3 to March 23 2020, 494 consecutively admitted COVID-19 patients received tocilizumab or standard treatment alone. Data were obtained retrospectively. Clinical respiratory severity (CRS) stages were defined by patient oxygenation status and were also associated to scores of WHO clinical progression scale. We categorized patients in three stages, mild/moderate CRS1 (FiSpO2<0.35; WHO score 5), moderate/severe CRS2 (FiO2=0.5/high flow mask; WHO score 6) and severe/critical CRS3 (FiO2<80%/high flow/prone position or mechanical ventilation; score>6). The primary outcome was the composite of death or ICU admission in patients of stages CRS1, CRS2, and CRS3, as well as in total patients. We also addressed mortality alone in total patients. Kaplan-Maier curves, Cox proportional regression and inverse probability weighting marginal structural models were used. We conducted the study from March 3 to April 7 2020 with broad-ranged severity patients; 167 tocilizumab-treated and 327 untreated. CRS1 patients showed no apparent benefit after treatment, while the risk of the primary outcome was greatly reduced in CRS2 treated participants ((HR=0.22; 95% CI (0.16-0.44)). Moreover, tocilizumab treatment was associated with significantly decreased CRS2 patient proportion that reached the outcome compared to non-treated controls (27.8.0% vs. 65.4%; p<0.001). Severe/critical CRS3 patients, also showed benefit after treatment (HR=0.38; 95% CI (0.16-90)), although not as robust as was that of CRS2 treated individuals. Tocilizumab was associated with reduced outcome risk in total patients (HR=0.42; 95% CI (0.26-0.66)) after CRS adjustment, but not if CRS classification was not accounted as confounding factor (HR=1.19; 95% CI (0.84-1.69)). The outcome of mortality alone upon tocilizumab treatment was significant (HR=0.58; 95% CI (0.35-0.96)) after accounting for CRS classification. Conclusions: Tocilizumab treatment is associated with reduced COVID-19 escalation in CRS2 patients, suggesting efficacy in moderate/severe non-ICU-admitted patients. CRS classification could represent an essential confounding factor in evaluating tocilizumab in studies of broad-ranged severity patients.

4 but not if CRS classification was not accounted as confounding factor (HR=1.19; 95% CI (0.84-1.69)). The outcome of mortality alone upon tocilizumab treatment was significant (HR=0.58; 95% CI (0.35-0.96)) after accounting for CRS classification.

Conclusions: Tocilizumab treatment is associated with reduced COVID-19 escalation in CRS2 patients, suggesting efficacy in moderate/severe non-ICU-admitted patients. CRS classification could represent an essential confounding factor in evaluating tocilizumab in studies of broad-ranged severity patients.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 9, 2021. ; https://doi.org/10.1101/2021.03.04.21252167 doi: medRxiv preprint INTRODUCTION 1 severely ill patients [24] , while the RECOVERY trial demonstrated that tocilizumab reduces 23 mortality in patients receiving corticosteroids [25] . Recent meta-analysis found an association 24 between tocilizumab and improved outcomes in moderate and severe patients (non-ICU), as 25 well as in critically ill patients (ICU) [26] . 26 We conducted a retrospective cohort study of 494 consecutively admitted COVID-19 27 patients that were classified in stages according to their Clinical Respiratory Severity (CRS). 28 We provide evidence that tocilizumab is associated with reduced disease escalation in a CRS-29 depending manner, and that CRS classification is a critical confounding factor to be 30 accounted for upon evaluation of tocilizumab's therapeutic potential in the global patient 31 population. 32 33 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 9, 2021. ; https://doi.org/10.1101/2021.03.04.21252167 doi: medRxiv preprint

Patients 36

Patients positive for SARS-Cov-2 from March 3 to March 23 2020 who met the 37 conditions of (1) respiratory rate ≥ 30 breaths/min, (2) SpO 2 ≤ 94% while breathing ambient 38 air, and (3) thorax X-ray with opacities, were included in the study, as defined by the 39 Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (6th interim edition) 40 [27] . 41

We obtained demographic data, as well as comorbidities (cancer, diabetes mellitus, 42 cardiovascular disease, chronic kidney disease, among others) from electronic health records. 43

We registered clinical symptoms, time of disease onset and laboratory and radiological data. 44

Standard treatment (ST) included lopinavir/ritonavir, hydroxychloroquine, IFN-β and 45 azithromycin in case of secondary infections (Supplementary Table 1 ). IFNβ administration 46 depended on the comorbidity extent and on age (> 65 years old). Two doses of IFNβ (at 47 admission and at 48 h, discontinued then after due to apparent patient worsening) were given 48 to 89 tocilizumab-treated patients and to 90 controls. At admission, patients received oxygen 49 support though low-flow nasal cannula to maintain SpO 2 >90%. Patients with increased 50 oxygen needs were switched to high-flow oxygen mask (Venturi mask up to 50% FiO 2 ). 51

Mechanical ventilation (MV) was provided only to ICU admitted patients. Considering the 52 critical situation at the hospital, access to ICU was limited and patients that would otherwise 53 be admitted to ICU were treated on the ward. 54 Patient selection for tocilizumab treatment depended on the study design, the availability 58 of tocilizumab and on ethical decisions, based on patient evolution during the time between 59 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) Initially, patient severity was considered on the basis of SpO 2 measurements on ambient 80 air and/or after low-flow oxygen supply during initial observation (24 hours or less). The 81 groups were defined by patients with SpO 2 >90% (corresponding to CRS1), 80%<SpO 2 <90% 82 (corresponding to CRS2), and SpO 2 <80% (corresponding to CRS3). By the end of the study 83 we considered that we had enough patients in order to proceed to statistical analysis. This 84 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) 

The primary outcome of the study was composite of death or admission to the ICU after 92 tocilizumab treatment of CRS1, CRS2 and CRS3 stage patients, as well as of the total patient 93 population. 94

In the secondary analysis death alone was conducted as endpoint, counting all in-hospital 95 deaths of the patients. Deaths that occurred after ICU admission were available from hospital 96 records and were also included in the analysis. 97

Descriptive statistics were used to summarize the data; age and days between onset of 99 symptoms and hospital admission were reported as means and standard deviations, and 100 laboratory results are reported as medians and interquartile ranges (IQR). Categorical 101 variables were summarized as counts and percentages. Associations between patient 102 characteristics and tocilizumab treatment were evaluated; in the case of categorical variables, 103

we used a Pearson's chi-squared or Fisher exact test, and in the case of quantitative variables, 104

Student's t test, the Mann-Whitney's U test, or Wilcoxon's test, as appropriate. No imputation 105 was made for missing data and no sample size calculations were performed. 106

We conducted a Cox proportional regression model with fixed covariates of patients from 107 the day of treatment to the day of ICU admission or death for the different patient CRS stages 108 adjusting for age, sex and IFN-β treatment. For total patients Cox analysis was also adjusted 109 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 9, 2021. ; https://doi.org/10.1101/2021.03.04.21252167 doi: medRxiv preprint for CRS stages (CRS1, CRS2, CRS3). The start date of the follow-up was the day they 110 received the medication. There were no differences in censorship for hospital discharge in 111 both treated and untreated groups. We tested the proportional-hazards assumption on the basis 112 of Schoenfeld residuals. This model may produce biased effect estimates when there are time-113 dependent confounders, which are affected by previous treatment or exposure. In this study, 114 the CRS status is both a time-dependent confounder of the causal effect of the treatment on 115 survival and is affected by past treatment [34, 35] . We thus conducted a marginal structural 116 model to estimate the causal effect of tocilizumab on the severe COVID-19 patients. We 117 carried out an unweighted pooled logistic regression, treating each person-day as an 118 observation (model 2). We fitted a pooled logistic regression weighted by the inverse-119 probability-of-treatment (IPWT). Each patient in the above logistic model received a time-120 varying weight inversely proportional to the estimated probability of having his/her own 121 observed history of tocilizumab initiation, as described [34, 36] . This weighting means that 122 observations on the same subject will correlate, we therefore used the robust standard errors 123 for clustering. Follow-up start day was the day of admission. 124

All models were adjusted for CRS stages (unless otherwise mentioned), sex, age, and 125 IFN-β treatment. All statistical analyses were performed using STATA v14 SE or SPSSv26. 126

RESULTS 128

We included 494 consecutively admitted patients, positive for SARS-CoV-2 and COVID-129 19 pneumonia. 167 patients received tocilizumab, while 327 did not ( Figure 1 ). Age, gender 130 distribution and frequency of comorbidities were similar for both groups (Table 1) . Disease 131 was classified in stages CRS1, CRS2 and CRS3 according to severity. Due to clinical 132 selection, CRS2 and CRS3 stages had higher proportions of treated than untreated patients 133 (Table 1) . Occurrence of secondary infections was minimal (<5%) by both patient groups, and 134 no opportunistic infections were recorded. 135 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 9, 2021.

CRS definition was validated after data collection. First, age, sex and comorbidities were 137 found balanced within the CRS1, CRS2 and CRS3 stages ( Analysis of the tocilizumab effect on the primary outcome for CRS1, CRS2 and CRS3 157 patients included Kaplan-Meier survival curves and multivariate Cox regression after 158 adjusting for age, sex and the IFN-β impact. In CRS1 patients, tocilizumab did not show an 159 apparent effect in lowering the outcome risk (HR=0.76 95% CI (0.34, 1.70)) ( Figure 2A ). 160 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 9, 2021. ; https://doi.org/10.1101/2021.03.04.21252167 doi: medRxiv preprint Although the percentage of CRS1 patients that reached the endpoint was reduced (23.5% 161 untreated vs. 15.6% treated), the results lacked significance ( Figure 2B ). On the other hand, 162 the data show significantly delayed outcome in tocilizumab treated CRS2 and CRS3 patients 163 ( Figure 2A) . A benefit was probable to occur for CRS2 treated patients (HR=0.22 95% CI 164 (0.16, 0.44)) and for CRS3 patients (HR=0.38 95% CI (0.16, 0.90)) ( Figure 2A ). Moreover, 165 our data indicated that tocilizumab could significantly reduce the proportion of CRS2 patients 166 that reached the endpoint (65.4% untreated vs. treated 27.8% patients; p<0.001) ( Figure 2B) . 167

Such reduction appeared to be not significant for treated CRS3 patients, possibly due to the 168 low number of untreated patients in CRS3. These data suggest that tocilizumab could be most 169 effective when administered to CRS2 stage patients. 170

In the entire treated population, tocilizumab greatly reduced CRP levels and elevated 171 lymphocyte concentrations 48 h post-treatment (Supplementary Table 2 accounted for CRS stage classification as confounding variable, in addition to age, sex and 175 the impact of IFN-β. We showed an association between tocilizumab treatment and reduced 176 risk of reaching the composite outcome ( Figure 3A and Table 3 , model 1). 177

In secondary analysis, Cox evaluation including the above adjustments, also indicated 178 reduced risk for mortality alone after tocilizumab treatment, considering all hospital deaths 179 (HR=0.58 95% CI (0.35, 0.96)). 180

Disease status of COVID-19 patients was a decisive confounding factor to be accounted 181 for regression analysis for our broad-ranged population. Notably, Cox analysis, that did not 182 account for CRS stages but included all other mentioned confounding parameters, showed no 183 effect of tocilizumab in reducing the risk for the composite outcome (HR=1.19 CI 95% (0.84-184 1.69)) ( Figure 3B and Supplementary Table 3) . 185 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 9, 2021. ; https://doi.org/10.1101/2021.03.04.21252167 doi: medRxiv preprint

In addition to Cox based evaluation in all patients, we conducted an unweighted pooled 186 logistic regression analysis for death or ICU admission and a weighted pooled logistic 187 regression by IPWT (Table 3 , models 2, 3). These models indicated that tocilizumab relates 188 with a reduced risk in patient mortality or ICU admission, and that age, but not sex, 189 significantly increased the risk for the end event. The risk for the outcome was significantly 190 increased by IFN-β treatment, at least by model 1. Importantly, the three models confirmed 191 that the patients' CRS stage is a significant risk factor for death or ICU admission and 192 confirmed that the CRS2 that CRS3 patients, as compared to CRS1, present a significantly 193 higher probability of reaching the end event. showing that after oxygen supplementation, SpO 2 >90% predicted survival, while SpO 2 <90% 206 levels were associated with COVID-19 escalation [42] . Results obtained during the study, 207 such as CRP levels, SpO 2 /FiO 2 and estimated PaO 2 /FiO 2 ratios further validated CRS stage 208 classification and corroborated the stage severity CRS1< CRS2< CRS3. Further refining of 209 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 9, 2021. When global patient population was considered, three models of regression analysis 232

showed that tocilizumab was associated with a reduced risk of the composite outcome, after 233 accounting for CRS stage classification as a confounding factor together with patient age, sex 234 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 9, 2021. Our study has the following limitations. First, the study was performed in one hospital and 254 was not randomized as tocilizumab treatment was prioritized for worsening patients within 255 the same CRS stage. Second, CRS3 stage patient population did not get the support of MV 256 due to the near collapse conditions in Spain at the time of the study. Third, our study was not 257 blinded and therefore a bias for ICU admission could favor untreated patients; this limitation 258 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 9, 2021. ; https://doi.org/10.1101/2021.03.04.21252167 doi: medRxiv preprint was minimized as analysis of overall hospital mortality as an endpoint showed benefit after 259 tocilizumab treatment. 260

The strengths of this study include the newly applied patient classification in CRS stages. 261

This later point is crucial since previous studies mostly found no tocilizumab effect when 262 considering patients of wide range disease severity. Several analyses were performed, with 263 consistent results across the models. Oxygen supplementation was uniform especially for the 264 CRS2 stage, as the vast majority of the patients were managed on the floor (i.e. not in the 265 ICU) on steady FiO 2 , avoiding the bias of oxygen supplementation in influencing the 266 outcome. Finally, although differences in tocilizumab efficacy have been suggested to depend 267 on disease stage, here we show this in a single study that encompassed three disease stages. 268

Tocilizumab shows variable efficacy, depending on three COVID-19 clinical respiratory 270 severity (CRS) stages. Treatment had no apparent benefit in CRS1 patients, but was 271 associated with a remarkable benefit in CRS2 patients, suggesting that tocilizumab could 272 target stages that did not require ICU care. These findings could contribute to define the 273 optimal point for treatment initiation. In general terms, our results indicate that the CRS-274 associated efficacy of tocilizumab could eventually hinder evaluation of its therapeutic effect, 275 and suggest the possibility to consider CRS patient classification as a confounding factor in 276 analyzing the efficacy of tocilizumab. These conclusions could assist in designing and/or 277 interpreting randomized clinical trials. 278 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 9, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 9, 2021. Tocilizumab discontinuation after attaining remission in patients with rheumatoid 302 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 9, 2021. ; . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 9, 2021. ; https://doi.org/10.1101/2021.03.04.21252167 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 9, 2021. ; https://doi.org/10.1101/2021.03.04.21252167 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 9, 2021. ; https://doi.org/10.1101/2021.03.04.21252167 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 9, 2021. ; https://doi.org/10.1101/2021.03.04.21252167 doi: medRxiv preprint Figure 3 A B

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 9, 2021. ; https://doi.org/10.1101/2021.03.04.21252167 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 9, 2021. ; https://doi.org/10.1101/2021.03.04.21252167 doi: medRxiv preprint

Estimating 279 clinical severity of COVID-19 from the transmission dynamics in Wuhan

Coronavirus disease 2019 (COVID-19): a clinical update

Clinical course and risk factors for 284 mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort 285 study

Patients Hospitalized with Covid-19 Pneumonia

Interleukin-6 Receptor Antagonists in Critically Ill Patients with 359

RECOVERY Collaborative Group

COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, 363 platform trial

Comparative efficacy and safety of 366 pharmacological interventions for the treatment of COVID-19: A systematic review 367 and network meta-analysis

Characteristics IE. Diagnosis and Treatment Protocol for Novel Coronavirus 370

Pneumonia (Trial Version 6, Revised)

A minimal 372 common outcome measure set for COVID-19 clinical research

Acute respiratory distress syndrome: The Berlin definition

of SpO2/FiO2serves as a noninvasive prognostic marker for intensive care patients 408 with COVID-19

Hypoxemia and Mortality in Patients With COVID-19

Time to Reassess Tocilizumab's Role in COVID-19 Pneumonia

COVACTA trial raises questions about tocilizumab's benefit in COVID-19

Between Early Treatment With Tocilizumab and Mortality Among Critically Ill 418

Patients With COVID-19

Tocilizumab in patients with severe COVID-19: a retrospective cohort study